冠心病合并焦虑抑郁的治疗研究进展
CSTR:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

基金项目:

首都临床特色应用研究与成果推广项目(Z161100000516136)


Research Progress in the Treatment of Coronary Heart Disease with Anxiety and Depression
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    冠心病合并焦虑抑郁的发病率逐年升高,但是识别率和诊治率较低。目前西医认为其发病机制可能与炎症反应、神经内分泌学说、血小板活化、内皮损伤等相关;中医认为气血阴阳亏损以及气滞、血瘀、痰浊为主要病因病机。治疗方式主要是在冠心病二级预防的基础上,联合中西医药物及非药物治疗焦虑抑郁,有效控制其危险因素。现主要对冠心病合并焦虑抑郁的发病机制及治疗进展进行报道。

    Abstract:

    The morbidity of coronary heart disease with anxiety and depression increases year by year,but its recognition rate and diagnosis and treatment rate are low.At present,western medicine believes that the pathogenesis of coronary heart disease with anxiety and depression may be related to inflammatory reaction,neuroendocrine system,platelet activation,endothelial injury,etc.,while traditional Chinese Medicine(TCM) holds that the deficiency of Qi,blood,Yin and Yang,Qi stagnation,blood stasis,turbid phlegm are the main etiology and pathogenesis.The treatment is mainly based on secondary prevention of coronary heart disease,combined with traditional Chinese and western medicine and non-drug treatment of anxiety and depression,to effectively control the risk factors.This paper reviewed the pathogenesis and treatment of coronary heart disease with anxiety and depression.

    参考文献
    相似文献
    引证文献
引用本文

史金玉,王超,黄乐曦,赵海滨.冠心病合并焦虑抑郁的治疗研究进展[J].世界中医药,2022,(14).

复制
相关视频

分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2020-10-31
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2022-09-01
  • 出版日期:
文章二维码